Company Overview and News

Philip Morris Places Bets On Health Benefits As Traditional Tobacco Contends With Legalized Cannabis

2h seekingalpha
Philip Morris International is set to unveil its third quarter of 2018 earnings Thursday, as the industry undergoes radical shifts in product offerings, innovation, and regulatory scrutiny.

KLCI gains after US equities' overnight rise

3h theedgemarkets
KUALA LUMPUR (Oct 17): The FBM KLCI gained 3.75 points or 0.22% today with Asian shares after US equities' overnight rise.
HLFBF 3867 5819 1082 BATS 4162 2836 5246

SJM seeks Narendra Modi#39;s intervention in keeping ITC in Indian hands

2018-10-16 moneycontrol
The RSS-affiliated Swadeshi Jagran Manch (SJM) sought Prime Minister Narendra Modi's intervention to ensure that the controlling stake in multi-business conglomerate ITC does not go to a foreign company.
BATS 4162

UPDATE 2-British American Tobacco cuts sales target for new products

2018-10-16 reuters
LONDON (Reuters) - British American Tobacco (BATS.L) cut its full-year revenue target for cigarette alternatives such as vaping pens and tobacco heating devices, citing a flat market in Japan and a product recall in the United States.
PM BATS 4162

BAT warns currency moves will harm profit growth

British American Tobacco, the world’s biggest cigarette manufacturer, has warned that currency movements will reduce its profit growth by around 7pc.
BATS 4162

UPDATE 1-UK Stocks-Factors to watch on Oct 16

2018-10-16 reuters
Oct 16 (Reuters) - Britain’s FTSE 100 index is seen opening 1 point higher at 7,031 with FTSE 100 futures up 0.01 percent ahead of the cash market open on Tuesday.

KLCI pares gains as sellers outpace buyers

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819

KLCI off to muted start as key Maybank, CIMB drag

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI started off on a muted note this morning against teh backdrop of modest gains at regional markets, as key index-linked heavyweights dragged.
5183 MLYBY PECGF MLYNF BATS 4162 5246 7022 9059 CIMDF GBTKF 1155 1023

KLCI reverses loss, tracks modest regional gains

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI reversed its earlier losses and climbed at mid-morning, tracking the modest rise at the regional markets.
UPBMF 5220 7113 5681 TPGVF BATS 4162 2291 2089 5014 7066 0131 6033 7123 5199 TGLVY 4588 PNADF 0026 MYPRY HIPEF PNAGF GEBHF

Philip Morris (PM) Q3 Earnings: Cigarette Woes Dim Prospects

2018-10-15 zacks
Philip Morris International Inc. (PM - Free Report) is slated to release third-quarter 2018 results on Oct 18, before the opening bell. The company has a mixed record of earnings surprises in the trailing four quarters. Let’s take a look at the factors that are likely to impact this tobacco giant’s upcoming quarterly announcement. Estimates for the Quarter The Zacks Consensus Estimate for third-quarter 2018 earnings is currently pegged at $1.

'Independent' doctor-led vaping group accepts tobacco-tainted funding

A charity spearheading efforts to legalise the nicotine vaping in Australia has accepted funding from an overseas group with clear links to tobacco multinationals.
PM BATS 4162

KLCI declines amid trade dispute, US rate hike concerns

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI closed two points or 0.12% lower after Asian equities declined on US-China trade dispute and US interest rate hike concerns.
BATS 4162 BSMAF 9334 1818

Britain’s FTSE relatively stable as Brexit impasse has mixed impact

2018-10-15 malaymail
MILAN, Oct 15 — Britain’s top share index was steady today as a deadlock in Brexit talks depressed domestic stocks but helped internationally focused companies as it weakened the pound.

Stock price decline leaves John Keells (JKH) vulnerable to a takeover by Sri Lanka’s oligarchs

2018-10-14 lankabusinessonline
Krishan Balendra during a Bloomberg Television interview in Hong Kong. Photographer: Lam Yik Fei/Bloomberg via Getty Images

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...